These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16421484)

  • 1. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Baek JH; Kim JG; Suh JS; Lee KB
    Transplantation; 2006 Jan; 81(1):101-8. PubMed ID: 16421484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
    Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
    Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
    Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
    Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution.
    Leserer S; Bayraktar E; Trilling M; Bogdanov R; Arrieta-Bolaños E; Tsachakis-Mück N; Crivello P; Koldehoff M; Maaßen F; Ross RS; Fleischhauer K; Beelen DW; Turki AT
    Am J Hematol; 2021 Apr; 96(4):436-445. PubMed ID: 33439488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis.
    Ando T; Suzuki T; Ishiyama Y; Koyama S; Tachibana T; Tanaka M; Kanamori H; Nakajima H
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):171-177. PubMed ID: 31563574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
    Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
    Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
    Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Analysis of Early CD4
    Leserer S; Arrieta-Bolaños E; Buttkereit U; Beelen DW; Turki AT
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type.
    Yokoyama H; Takenaka K; Nishida T; Seo S; Shinohara A; Uchida N; Tanaka M; Takahashi S; Onizuka M; Kozai Y; Yasuhiro S; Ozawa Y; Katsuoka Y; Doki N; Sawa M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Nakasone H;
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1363-1370. PubMed ID: 32311477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and survival of refractory cytomegalovirus reactivation after allogeneic peripheral blood stem cell transplantation.
    Duan Z; Zhang X; Liu Y; Li F; Shen H; Chen R; Zhu H; Qiu H; Miao K
    J Glob Antimicrob Resist; 2022 Dec; 31():279-285. PubMed ID: 36265801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Perrone T; Carluccio P; Gaudio F; Giordano A; Rossi AR; Ricco A; Leo M; Liso V; Specchia G
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):550-7. PubMed ID: 20457268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.